1 – 31 of 31
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
(
- Contribution to journal › Article
- 2022
-
Mark
Mental health and psychosocial consequences linked to radiation emergencies - Increasingly recognised concerns
(
- Contribution to journal › Scientific review
-
Mark
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
(
- Contribution to journal › Article
- 2021
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2017
-
Mark
Kronisk myeloisk leukemi : Förebild för målstyrd terapi
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Kronisk myeloisk leukemi : förebild för målstyrd terapi - Revolutionerande överlevnadsvinster med definitiv bot i sikte och kraftigt förbättrad hälsoekonomi
(
- Contribution to journal › Article
-
Mark
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia
(
- Contribution to journal › Article
-
Mark
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
-
Mark
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article
-
Mark
Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
- 2014
-
Mark
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
(
- Contribution to journal › Letter
- 2013
-
Mark
Medicinska framsteg i behandling av kronisk myeloisk leukemi
2013)(
- Other contribution › Miscellaneous
-
Mark
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
(
- Contribution to journal › Article
- 2012
-
Mark
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2010
-
Mark
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
(
- Contribution to journal › Article
-
Mark
The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph plus ) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy plus G-CSF in patients with chronic myelogenous leukemia in first chronic phase
(
- Contribution to journal › Article